4Tech, which is developing a transcatheter device (TriCinch) for repair of the tricuspid valve, has announced that it has appointed Paul Cornelison, as Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs. Most recently, Paul was Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs at CardiAQ Valve Technologies, a developer of Transcatheter Mitral Valve Replacement (recently acquired by Edwards Lifesciences).
A press release reports that previously Paul served as Vice President of Regulatory Affairs & Quality Assurance at Cardiac Dimensions—one of the earliest percutaneous mitral valve repair companies. Earlier in his career, he held regulatory and quality assurance positions at Arrow International (now part of Teleflex Medical), RCRI, St Jude Medical (Daig Division), Angeion Corporation, Telectronics Pacing Systems, Aequitron Medical and Lake Region Manufacturing. He holds a master’s degree in Engineering (Management of Technology) from the University of Pennsylvania, and bachelors of arts degrees in Management and Spanish from St Johns’ University (MN).
Carine Schorochoff, co-Founder and chief executive officer of 4Tech, says: “Paul offers a broad range of quality, regulatory and clinical experience from nearly 25 years in the medical device industry, and has been a pioneer in the field of transcatheter valve therapies. As we finalise our second-generation 4Tech TriCinch system and prepare to start definitive clinical trials, I cannot think of anyone more qualified to pave the way for the European approval of the first transcatheter tricuspid repair technology.”
